MarketResearch.biz delivers in-depth insights on the global cancer diagnostics market in its upcoming report titled, “Global Cancer Diagnostics Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026”. The global cancer diagnostics market is estimated to register a CAGR of XXX% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2026. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cancer diagnostics market report has been segmented on the basis method, application and region.
Cancer is second most frequent cause of death in humans around the world. Cancer is a class of diseases characterized by uncontrolled growth of cells. Cancer diagnosis is currently undergoing a paradigm shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. Cancer diagnosis begins with a physical exam and laboratory tests to assess the staging of disease which is necessary for planning of treatment. Multiple platforms and growing technological advances enable faster and cheaper analysis cancer. The ultimate goal of cancer diagnosis is to identify the correct stage of disease guide the therapy so that every patient received precision medicine that is the right drug at the right dose. According to WHO, in 2015 8.8 million people worldwide died from cancer.
Key driver of global cancer diagnostics market is increasing global incidence of cancer along with different forms of cancer. In addition, change in lifestyle, increasing consumption of cigarette smoking, physical inactivity, excess alcohol consumption, poor nutrition are the factors anticipated to propel growth of the global cancer diagnostics market. However, high cost of diagnostics procedure and poor reimbursement policies may hinder growth of global cancer diagnostics market.
Various trends witness in cancer diagnostics market are, new technologies and therapies such as fluid biopsy, real-time cancer diagnostics and networking sites such as smart patients etc. Government and other local bodies are taking initiative in spreading the awareness of treatment and diagnosis of cancer. Player in this industry are Focusing on diagnostics, quality and payment for genetic cancer tests.
The market in North America is expected to dominate market of the global cancer diagnostics market, due to increasing incidence of cancer in this region. According to American Cancer Society, in 2016 about 595,690 Americans died of cancer. The market in Asia Pacific is expected to be emerging market of the global cancer diagnostics market, owing to rising initiatives of government to support cancer awareness, high adoption rate of preventive diagnostic techniques. Asia Pacific cancer diagnostics market is also projected to register highest growth in terms of revenue in the next five years.
Global Cancer Diagnostics Market Segmentation:
Segmentation by method:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Enzyme-Linked Fluourescent Assay (ELFA)
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT scan)
- Positron Emission Tomography (PET)
- Others (barium enema, serological method etc.)
Segmentation by application:
- Breast cancer
- Colorectal cancer
- Cervical cancer
- Lung cancer
- Prostate cancer
- Skin cancer
- Blood cancer
- Kidney cancer
- Liver cancer
- Pancreatic cancer
- Ovarian cancer
- Other (Esophageal cancer, Brain cancer etc.)
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2027 Revenue in US$
- Thermo Fisher Scientific Inc.
- Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Becton, Dickinson and Company
- Agilent Technologies, Inc.
- Roche Diagnostics GmbH
- QIAGEN N.V.
- Illumina, Inc.
- Eli Lilly and Co.
- Philips Healthcare Informatics, Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!